Anti-Hu CD79b Purified

*Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89 (18) :8522-6., URL: https://www.ncbi.nlm.nih.gov/pubmed/1382292, *Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8 (10) :2937-46., URL: https://www.ncbi.nlm.nih.gov/pubmed/19808977, *Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct;13 (10) :1501-5., URL: https://www.ncbi.nlm.nih.gov/pubmed/10516749, *Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95 (8) :2725-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/10753858, *Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114 (13) :2721-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/19633198, *Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55 (3) :180-3., URL: http://www.ncbi.nlm.nih.gov/pubmed/11896067 , *D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85 (5) :556-7., URL: http://www.ncbi.nlm.nih.gov/pubmed/10800181